Navigation Links
Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
Date:12/20/2010

SAN DIEGO, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy. Consistent with the severity and rare nature of the disorder, Amylin has received both orphan drug designation from FDA's Office of Orphan Products Development, as well as Fast Track designation for the use of metreleptin in patients with lipodystrophy. The focus of this marketing application is on rare inherited and acquired forms of lipodystrophy.

In the first part of its rolling submission, the Company submitted the nonclinical and clinical sections of the BLA. The Company plans to submit the chemistry, manufacturing and controls (CMC) section of the BLA by the end of 2011, which will complete the submission.

"It is gratifying to see that, after years of research focused on leptin as an effective therapy for lipodystrophy, we are now closer to bringing this important and innovative medicine to patients who are in dire need of better treatments," said Phillip Gorden, M.D., Director Emeritus, Senior Investigator, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Dr. Gorden is the principal investigator of an ongoing NIH clinical study evaluating the long-term efficacy of metreleptin treatment in lipodystrophy.

Lipodystrophy syndromes are characterized by abnormalities in adipose (fat) tissue distribution with loss of subcutaneous fat, and often manifest in childhood or adolescence. Patients with lipodystrophy can have multiple severe metabolic abnormalities, includin
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 Research and ... of the  "Global Operating Room Equipment Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating room ... in a healthcare facility used to perform ... advanced equipment, which ensures patient care and ...
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. ... , the Canadian Medical Association (CMA) voted on ... any plant material, including medicinal cannabis. Bedrocan Cannabis Corp., ... supportive of the CMA motion. The CMA ... particular hazards associated with smoking any plant material, including ...
(Date:8/22/2014)... Research and Markets has announced ... Catheter Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global and Chinese Intravenous Catheter Industry Report 2014 2
... 2012  The United States Patent & Trademark Office (USPTO) ... BDSI ) that the USPTO has rejected all claims ... No. 7,357,891 (the ,891 Patent) which is currently being ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ...
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) ... provide this corporate update detailing the Company,s business ... acquisition of its wholly owned subsidiary Healthcare Distribution ... sector.  The U.S. pharmaceutical distribution sector is approximately ...
Cached Medicine Technology:US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 2US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 3Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector 2Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector 3
(Date:8/23/2014)... Albany, New York (PRWEB) August 23, 2014 ... invasive surgeries done to remove plaques, etc, thereby addressing ... surgeries restore the flow of blood to the other ... the flow of oxygenated blood. These procedures require the ... made of metal composites and polymers), these catheters are ...
(Date:8/23/2014)... PA (PRWEB) August 23, 2014 Having been ... and dental hygienist from Arlington, Texas, saw a need for ... and toothpaste. "That’s when I came up with the idea ... No-Brush provides an effective way for a user to clean ... need to carry multiple items. It also helps avoid plaque ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 A team of ... mesothelioma last longer when preceded by surgery and delivered by ... on the new study. Click here to read it ... studied the cases of mesothelioma patients who underwent ... conforming radiotherapy dose to the shape of a tumor. ...
(Date:8/23/2014)... August 23, 2014 Legal Insider ... created by Greg Marks has been generating a buzz ... month. The commotion surrounding the new product has drawn ... review. , “In recent years the market ... systems, commonly referred to as robots or ‘bots,'” reports ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
Breaking Medicine News(10 mins):Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3
... Southeast Florida Market, NORTH HOLLYWOOD, Calif., Aug. ... IPCM ), a leading national hospitalist,physician group practice, ... of Hospitalists of America (HOA). The acquisition,expands IPC,s ... with a network of independent physicians, who perform ...
... InteKrin Therapeutics, Inc.,a clinical stage biopharmaceutical company ... and obesity today announced it has,completed the first ... $18.25,million. The financing was led by Skyline Ventures ... Ph.D. of Skyline will join InteKrin,s Board of,Directors. ...
... (Nasdaq:,EVVV), a global endovascular device company, today announced the,appointment ... effective,immediately. Mr. Kohrs will also serve as a member ... director of ev3 from June 2005,until October 2007 at ... the completion of ev3,s acquisition of FoxHollow Technologies,Inc., ...
... the Virginia Bioinformatics Institute (VBI) at Virginia Tech have ... proteins in oomycete plant pathogens that enables the proteins ... region contains the amino acid sequence motifs RXLR and ... proteins across the membrane surrounding plant cells without any ...
... less rest linked to doubled chance of weight gain, study ... little sleep or not spending enough time in rapid eye ... and teens, a new U.S. study. , For three consecutive ... 7 to 17. They looked at total sleep time, time ...
... Study finds that older patients, concerns often go unspoken and ... ... surgery with,their orthopaedic surgeons, older patients frequently do not raise all of,their ... The Journal of Bone and Joint Surgery found that patients age,60 or ...
Cached Medicine News:Health News:IPC The Hospitalist Company Completes Acquisition of Hospitalists of America 2Health News:InteKrin Therapeutics Announces $20 Million Series C Financing 2Health News:ev3 Inc. Appoints Douglas W. Kohrs to Board of Directors 2Health News:Key to virulence protein entry into host cells discovered 2Health News:Kids Who Sleep Poorly at Risk for Being Overweight 2Health News:Video: Communication is Key to Ease Worry about Orthopaedic Surgery 2Health News:Video: Communication is Key to Ease Worry about Orthopaedic Surgery 3
... Modular Incubator Chamber has been used worldwide ... conditions for gas mixture and temperature. This ... reliable for in vitro fertilization, HIV isolation, ... environmental contiftions, organ culture and the culturing ...
... range of miniTHERM incubators is available, ensuring ... solution for their specific requirements. miniTHERM incubators ... compact and extremely space saving. Their size ... It is possible to stack up to ...
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc....
3.0% Tryptone, 2.0% Yeast Extract, 1.0% MOPS free acid, 2.0% Glucose....
Medicine Products: